Treatment strategies for pelvic inflammatory disease

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Background: Pelvic inflammatory disease (PID) is one of the most common infections seen in nonpregnant reproductive-age women. It is a major public health problem associated with substantial medical complications (e.g., infertility, ectopic pregnancy, and chronic pelvic pain) and healthcare costs. Prevention of these long-term sequelae requires treatment strategies that are based on the microbiologic etiology of acute PID. Objective: To determine appropriate antimicrobial regimens for the treatment of acute PID based on published literature. Methods: Clinical trials published since 2002 were assessed conducting a systematic search of the literature on the treatment of acute PID using PubMed (National Library of Congress). The search was limited to articles written in English and published from 1 January 2002 to 30 June 2008. Results: Acute PID is a polymicrobic infection caused by both sexually transmitted organisms (primarily Neisseria gonorrhoeae and Chlamydia trachomatis) and microorganisms found in the endogenous flora of the vagina and cervix. The latter include anaerobic bacteria and facultative bacteria, many of which are associated with bacterial vaginosis. Genital tract mycoplasmas, most importantly Mycoplasma genitalium, may also be implicated in the etiology of acute PID. Because of this polymicrobial nature, currently available evidence, as well as recommendations by the CDC, support the use of broad-spectrum regimens (oral or parenteral) that provide adequate coverage against these microorganisms.

Original languageEnglish (US)
Pages (from-to)823-837
Number of pages15
JournalExpert Opinion on Pharmacotherapy
Volume10
Issue number5
DOIs
StatePublished - Apr 2009

Fingerprint

Pelvic Inflammatory Disease
Therapeutics
Mycoplasma genitalium
Bacterial Vaginosis
Pelvic Pain
Anaerobic Bacteria
Neisseria gonorrhoeae
Mycoplasma
Ectopic Pregnancy
Chlamydia trachomatis
Vagina
Centers for Disease Control and Prevention (U.S.)
Infection
PubMed
Cervix Uteri
Chronic Pain
Health Care Costs
Infertility
Libraries
Public Health

Keywords

  • Acute salpingitis
  • Antimicrobial treatment
  • Pelvic inflammatory disease (PID)
  • Subclinical PID

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Treatment strategies for pelvic inflammatory disease. / Sweet, Richard L.

In: Expert Opinion on Pharmacotherapy, Vol. 10, No. 5, 04.2009, p. 823-837.

Research output: Contribution to journalArticle

@article{bb1f4509c51843c9871b67a1511df9fd,
title = "Treatment strategies for pelvic inflammatory disease",
abstract = "Background: Pelvic inflammatory disease (PID) is one of the most common infections seen in nonpregnant reproductive-age women. It is a major public health problem associated with substantial medical complications (e.g., infertility, ectopic pregnancy, and chronic pelvic pain) and healthcare costs. Prevention of these long-term sequelae requires treatment strategies that are based on the microbiologic etiology of acute PID. Objective: To determine appropriate antimicrobial regimens for the treatment of acute PID based on published literature. Methods: Clinical trials published since 2002 were assessed conducting a systematic search of the literature on the treatment of acute PID using PubMed (National Library of Congress). The search was limited to articles written in English and published from 1 January 2002 to 30 June 2008. Results: Acute PID is a polymicrobic infection caused by both sexually transmitted organisms (primarily Neisseria gonorrhoeae and Chlamydia trachomatis) and microorganisms found in the endogenous flora of the vagina and cervix. The latter include anaerobic bacteria and facultative bacteria, many of which are associated with bacterial vaginosis. Genital tract mycoplasmas, most importantly Mycoplasma genitalium, may also be implicated in the etiology of acute PID. Because of this polymicrobial nature, currently available evidence, as well as recommendations by the CDC, support the use of broad-spectrum regimens (oral or parenteral) that provide adequate coverage against these microorganisms.",
keywords = "Acute salpingitis, Antimicrobial treatment, Pelvic inflammatory disease (PID), Subclinical PID",
author = "Sweet, {Richard L}",
year = "2009",
month = "4",
doi = "10.1517/14656560902823816",
language = "English (US)",
volume = "10",
pages = "823--837",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Treatment strategies for pelvic inflammatory disease

AU - Sweet, Richard L

PY - 2009/4

Y1 - 2009/4

N2 - Background: Pelvic inflammatory disease (PID) is one of the most common infections seen in nonpregnant reproductive-age women. It is a major public health problem associated with substantial medical complications (e.g., infertility, ectopic pregnancy, and chronic pelvic pain) and healthcare costs. Prevention of these long-term sequelae requires treatment strategies that are based on the microbiologic etiology of acute PID. Objective: To determine appropriate antimicrobial regimens for the treatment of acute PID based on published literature. Methods: Clinical trials published since 2002 were assessed conducting a systematic search of the literature on the treatment of acute PID using PubMed (National Library of Congress). The search was limited to articles written in English and published from 1 January 2002 to 30 June 2008. Results: Acute PID is a polymicrobic infection caused by both sexually transmitted organisms (primarily Neisseria gonorrhoeae and Chlamydia trachomatis) and microorganisms found in the endogenous flora of the vagina and cervix. The latter include anaerobic bacteria and facultative bacteria, many of which are associated with bacterial vaginosis. Genital tract mycoplasmas, most importantly Mycoplasma genitalium, may also be implicated in the etiology of acute PID. Because of this polymicrobial nature, currently available evidence, as well as recommendations by the CDC, support the use of broad-spectrum regimens (oral or parenteral) that provide adequate coverage against these microorganisms.

AB - Background: Pelvic inflammatory disease (PID) is one of the most common infections seen in nonpregnant reproductive-age women. It is a major public health problem associated with substantial medical complications (e.g., infertility, ectopic pregnancy, and chronic pelvic pain) and healthcare costs. Prevention of these long-term sequelae requires treatment strategies that are based on the microbiologic etiology of acute PID. Objective: To determine appropriate antimicrobial regimens for the treatment of acute PID based on published literature. Methods: Clinical trials published since 2002 were assessed conducting a systematic search of the literature on the treatment of acute PID using PubMed (National Library of Congress). The search was limited to articles written in English and published from 1 January 2002 to 30 June 2008. Results: Acute PID is a polymicrobic infection caused by both sexually transmitted organisms (primarily Neisseria gonorrhoeae and Chlamydia trachomatis) and microorganisms found in the endogenous flora of the vagina and cervix. The latter include anaerobic bacteria and facultative bacteria, many of which are associated with bacterial vaginosis. Genital tract mycoplasmas, most importantly Mycoplasma genitalium, may also be implicated in the etiology of acute PID. Because of this polymicrobial nature, currently available evidence, as well as recommendations by the CDC, support the use of broad-spectrum regimens (oral or parenteral) that provide adequate coverage against these microorganisms.

KW - Acute salpingitis

KW - Antimicrobial treatment

KW - Pelvic inflammatory disease (PID)

KW - Subclinical PID

UR - http://www.scopus.com/inward/record.url?scp=67649576391&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649576391&partnerID=8YFLogxK

U2 - 10.1517/14656560902823816

DO - 10.1517/14656560902823816

M3 - Article

VL - 10

SP - 823

EP - 837

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 5

ER -